Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will ...